Liposomal annamycin-a new generation anthracycline that overcomes MDR and has no cardiac toxicity for the treatment of R/R AML

Authors
Category Primary study
JournalHemaSphere
Year 2019
This article has no abstract
Epistemonikos ID: 0a5b75483343d91f156a4c81fd699742f8e52c94
First added on: Feb 11, 2025